Cambridge Trust’s Corbus Pharmaceuticals CRBP Stock Holding History

Cambridge Trust’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-133	Closed	-$2K	–	966
2021 Q4	$2K	Buy	+133	New	+$3.6K	﹤0.01%	955

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Cambridge Trust's CRBP Position: Q1 2022 in Review

Cambridge Trust sold out of Corbus Pharmaceuticals (CRBP) in Q1 2022, closing a stake of 133 shares — an estimated $2K sold.

Cambridge Trust first reported a position in CRBP in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 72 funds tracked by Wall St. Rank hold CRBP as of Q1 2022.

Cambridge Trust reported no remaining Corbus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Cambridge Trust sold 133 Corbus Pharmaceuticals shares in Q1 2022, an estimated $2K.
Cambridge Trust first reported a position in Corbus Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Cambridge Trust's Corbus Pharmaceuticals position peaked at $2K in Q4 2021.
72 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2022.

Based on Cambridge Trust's 13F filing for Q1 2022, filed 12 May 2022.